SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 137,126.63 |
| Enterprise Value ($M) | 156,607.63 |
| Book Value ($M) | 19,246.00 |
| Book Value / Share | 15.44 |
| Price / Book | 7.12 |
| NCAV ($M) | -21,749.00 |
| NCAV / Share | -17.45 |
| Price / NCAV | -6.30 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.01 |
| Return on Assets (ROA) | 0.01 |
| Return on Equity (ROE) | 0.02 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.20 |
| Current Ratio | 1.50 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 18,000.00 |
| Assets | 58,995.00 |
| Liabilities | 39,749.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 28,754.00 |
| Operating Income | 10,869.00 |
| Net Income | 480.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 10,828.00 |
| Cash from Investing | -3,449.00 |
| Cash from Financing | -3,433.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 8.97 | -0.19 | |
| 13G/A | Capital World Investors | 6.70 | 21.48 | |
| 13G/A | BlackRock, Inc. | 9.90 | -6.66 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,237,363 | 6,251,835 | 19.79 | |
| 1,560,378 | 6,246,916 | 24.98 | |
| 1,204,564 | 4,804,644 | 25.07 | |
| 1,111,621 | 6,482,334 | 17.15 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| FGEN – FibroGen, Inc. | GBIO – Generation Bio Co. |
| GERN – Geron Corporation | GLUE – Monte Rosa Therapeutics, Inc. |
| GOSS – Gossamer Bio, Inc. |